AlphaGrep UK’s Amgen AMGN Stock Holding History

AlphaGrep UK’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-800	Closed	-$281K	–	737
2026 Q1	$281K	Buy	+800	New	+$285K	0.08%	545

Other funds holding AMGN

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

AlphaGrep UK's AMGN Position: Q3 2026 in Review

AlphaGrep UK sold out of Amgen (AMGN) in Q3 2026, closing a stake of 731 shares — an estimated $265K sold.

AlphaGrep UK first reported a position in AMGN in Q4 2025 and held it in 3 quarters. The position peaked at $379K in Q4 2025. 2,911 funds tracked by Wall St. Rank hold AMGN as of Q3 2026.

AlphaGrep UK reported no remaining Amgen position as of Q3 2026 after selling out during the quarter.
AlphaGrep UK sold 731 Amgen shares in Q3 2026, an estimated $265K.
AlphaGrep UK first reported a position in Amgen in Q4 2025 and held it in 3 quarters.
AlphaGrep UK's Amgen position peaked at $379K in Q4 2025.
2,911 funds tracked by Wall St. Rank held Amgen as of Q3 2026.

Based on AlphaGrep UK's 13F filing for Q3 2026, filed 12 Nov 2026.